Document is current

Article History

Received: 4 December 2020

Accepted: 9 January 2021

First Online: 22 January 2021

Ethics approval and consent to participate

: The study was conducted retrospectively and, as patients were not involved in its conduct, there was no impact on their care. Ethical approval was not required, as all data were anonymized. The French Data Protection Authority granted access to the PMSI data. Procedures for data collection and management were approved by the Commission Nationale de l'Informatique et des Libertés (CNIL), the independent National Ethical Committee protecting human rights in France, which ensures that all information is kept confidential and anonymous, in compliance with the Declaration of Helsinki (Authorization Number 1897139).

: Authors give the full consent to publish the present article.

: None directly related to the matter of this article. DA: Fees for lectures or consulting from Amgen, Alnylam, Sanofi, Novartis, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, Novo-Nordisk, Pfizer, and Servier. LF: Consultant or speaker activities for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, and Novartis. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. All other authors: None.